A novel perspective on pharmaceutical R&D costs: opportunities for reductions

Author:

van der Schans Simon12ORCID,De Loos Frans2,Boersma Cornelis13,Postma Maarten J.145,Büller Hans2

Affiliation:

1. Unit of Global Health, Department of Health Science, University Medical Centre Groningen, Groningen, the Netherlands

2. Fair Medicine Foundation, Amsterdam, the Netherlands

3. Faculty of Management Sciences, Open University, Heerlen, the Netherlands

4. Unit of PharmacoTherapy, -epidemiology & -economics (Pte2), Department of Pharmacy, University of Groningen, Groningen, the Netherlands

5. Faculty of Economics & Business, Department of Economics, Econometrics & Finance, University of Groningen, Groningen, the Netherlands

Funder

unding agency in the public

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Reference40 articles.

1. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018

2. Research and Development Spending to Bring a Single Cancer Drug to Market and Revenues After Approval

3. Innovation in the pharmaceutical industry: New estimates of R&D costs

4. Jacobs J, Livestro D, Oosterwaal M; The Cost of Opportunity - A Study on Pharmaceutical R&D Costs. 2019. https://gupta-strategists.nl/studies/the-cost-of-opportunity.

5. Hadjivasiliou A, Gardner J Orphan Drug Report. 2014. http://info.evaluategroup.com/rs/evaluatepharmaltd/images/2014OD.pdf.

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3